Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis

Journal of Rheumatology

Volumn 25, Issue 7, 1998, Pages 1282-1289

  Gough, Andrew ^a   Sambrook, Philip ^b   Devlin, Joe ^a   Huissoon, Aarnoud ^c   Njeh, Christopher ^d   Robbins, Simon ^e   Nguyen, Tuan ^b   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e ROWETT RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Bone markers; Bone mineral density; Bone turnover; Osteoporosis; Rheumatoid arthritis

Indexed keywords

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; DENSITOMETRY, X-RAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS;

EID: 0031838041     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. McConkey B, Fraser GM, Bligh AS. Osteoporosis and purpura in rheumatoid disease: prevalence and relation to treatment with corticosteroids. Q J Med 1962;31:419-27.
2. Saville PO. A quantitative approach to the simple radiographic diagnosis of osteoporosis: its application to the osteoporosis of rheumatoid arthritis. Arthritis Rheum 1967; 10:416-22.
3. Kennedy AC, Smith DA, Buchanan WW, Anderson JB, Jasani MK. Bone loss in patients with rheumatoid arthritis. Scand J Rheumatol 1975;4:73-9.
4. Hooyman JR, Melton LJ, Nelson AM, O'Fallon WM, Riggs BL. Fractures after rheumatoid arthritis. Arthritis Rheum 1984; 27: 1353-61.
5. Beat AM, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991;18:804-8.
6. Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993; 306:558.
7. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54:49-52.
8. Oka T, Rekonen A, Kuikka J, Anttinen J. Bone mineral density in rheumatoid arthritis measured by the gamma transmission method. Scand J Rheumatol 1975;4:28-32.
9. Hancock DA, Asiedu-Offei S, Atkinson PJ, Reed GW, Wright V. Femoral bone mass in patients with rheumatoid arthritis and osteoarthrosis. Rheum Rehab 1978;17:65-71.
10. Als OS, Gotfredsen A, Riis BJ, Christiansen C. Are disease duration and degree of functional impairment determinants of bone mass in rheumatoid arthritis. Ann Rheum Dis 1985;44:406-11.
11. Verstraeten A, Dequecker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
12. Laan RFJM, Buijs WCAM, Verbeek ALM, et al. Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis 1993;52:21-6.
13. Leboff MS, Wade JP, MacKowiac S, Fuleihan GE, Zangari M, Liang MH. Low dose prednisolone does not affect calcium homeostasis or bone density in post-menopausal women with rheumatoid arthritis. J Rheumatol 1991;18:339-44.
14. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
15. Gough AKS, Lilley J, Eyre S, Holder RL, Emery P. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23-7.
16. Fries JF. The dimensions of health outcomes: the Health Assessment Questionnaire. J Rheumatol 1982;74:786-93.
17. Duncan H, Frost HM, Villanueva AR, Sigler JW. The osteoporosis of rheumatoid arthritis. Arthritis Rheum 1965;8:943-54.
18. Compston JE, Vedi S, Mellish RWE, Croucher P, O'Sullivan MM. Reduced bone formation in non-steroid treated patients with rheumatoid arthritis. Ann Rheum Dis 1989;48:483-7.
19. Sambrook P, Ansell BM, Foster S, et al. Bone turnover in early rheumatoid arthritis. 1. Biochemical and kinetic indexes. Ann Rheum Dis 1985;44:575-9.
20. Robins SP, Stewart P, Astbury C, Bird HA. Measurement of the crosslinking compound, pyridinoline, in urine as an index of collagen degradation in joint disease. Ann Rheum Dis 1986;45:969-73.
21. Seibel MJ, Duncan A, Robins SP. Urinary hydroxy-pyridinium crosslinks provide indexes of cartilage and bone involvement in arthritic disease. J Rheumatol 1989;16:964-70.
22. Black D, Marabami M, Sturrock RD, Robins SP. Urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis. Ann Rheum Dis 1989;48:641-4.
23. Eggelmeijer E, Papapoulos SE, Westedt ML, van Passen HC, Dijkmans BAC, Breedveld FC. Bone metabolism in rheumatoid arthritis; relation to disease activity. Br J Rheumatol 1993;32:38791.
24. Spector TD, James IT, Hall GM, Thompson PW, Perrett D, Hart DJ. Increased levels of urinary collagen crosslinks in females with rheumatoid arthritis. Clin Rheumatol 1993;12:240-4.
25. Gough AKS, Peel NFA, Eastell R, Holder R, Lilley J, Emery P. Excretion of pyridinoline crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994;53:14-7.
26. Sinigaglia L, Varenna M, Binelli L, et al. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1995;54:144-7.
27. Arnett FC, Edworthy SM, Block DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-32.
28. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393-406.
29. Lilley J, Walters BG, Heath DA, Drolc Z. In vivo and in vitro precision for bone density measured by dual energy x-ray absorption. Osteoporosis Int 1991;1:141-6.
30. Pratt DA, Daniloff Y, Duncan A, Robins SP. Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Anal Biochem 1992;207:168-75.
31. Compston JE, Vedi S, Croucher PI, Garrahan NJ, O'Sullivan MM. Bone turnover in non-steroid treated rheumatoid arthritis. Ann Rheum Dis 1994;53:163-6.
32. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, Di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988;2:706-9.
33. Gowen M, Wood DD, Ihrie EJ, McGuire MKB, Russell RGG. An interleukin 1-like factor stimulates bone resorption in vitro. Nature 1983;306:378-80.
34. Thomson BM, Mundy GR, Chambers TJ. Tumour necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987;138:775-9.
35. Roodman GD. Interleukin 6: An osteotropic factor? J Bone Miner Res 1992;7:475-8.
36. Dasgupta B, Corkhill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992;19:22-5.
37. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumour necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
38. Gough A. Disease severity and prediction of outcome in early rheumatoid arthritis. MD Thesis, University of London; 1994.
39. Kelly PJ, Hopper JL, Macaskill T, Pocock NA, Sambrook PN, Eisman JA. Genetic factors in bone turnover. J Clin Endocrin Metab 1991;72:808-13.
40. Kroger H, Risteli J, Risteli L, Penttila I, Alhava E. Serum osteocalcin and carboxyterminal propeptide of type 1 procollagen in rheumatoid arthritis. Ann Rheum Dis 1993;52:338-42.
41. Hall GM, Spector TD, Delmas PD. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 1995;7:902-6.
42. Sambrook PN, Eisman J, Champion GD, Yeates MG, Pocock NA, Eberl S. Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 1987;30:721-8.
43. Gauldie J, Richards C, Harnish D, Lansdorf P, Baumann H. Interferon b2/B cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulatory factor (HSF) and regulates the major acute phase response in liver cells. Proc Natl Acad Sci USA 1987;84:7251-6.
44. van Leeuwen MA, Westra J, Limburg PC, van Riel PL, Rijswijk MH. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis 1995;54:674-7.
45. Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH, Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994;53:521-4.
46. van der Heijde DM, van Riel PL, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1993;31:519-25.
47. Devlin J, Gough A, Huissoon A, et al. The acute phase and function in early rheumatoid arthritis. C reactive protein levels correlate with functional outcome. J Rheumatol 1997;24:9-13.
48. Eggelmeijer F, Papaoulos SE, van Paassen HC, Dijkmans BAC, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994;21:2016-9.
49. MacDonald AG, Murphy EA, Capell HA, Bankowska UZ, Ralston SH. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 1994;53:54-7.